Clinical Trial Update: Safety of CHIR-258 (TKI258) in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This notice summarizes safety data from a Phase 1 study of CHIR-258 (TKI-258) in patients with advanced solid tumors. The trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• CHIR-258 (TKI-258)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neoplasms, Cancer | Phase 1 | Status: TERMINATED